Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses
- PMID: 29682323
- PMCID: PMC5905582
- DOI: 10.4155/fsoa-2017-0133
Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses
Abstract
Aim: Treatment of inflammatory disorders relies on the intervention in immune responses thereby restoring homeostasis. IL-10 is a cytokine with therapeutic potential, but until now has not been as successful as previously anticipated. A reason for this may be that IL-10 responsiveness depends on the environment of the inflamed tissue. In this study we investigated whether GM-CSF is able to influence IL-10-mediated responses.
Methodology: Dendritic cells and macrophages were differentiated from mouse bone marrow and treated or depleted from GM-CSF prior to analyze their response to IL-10. Activity was assessed by measuring cytokine expression upon lipopolysaccharide stimulation, IL-10-induced signaling and down-stream gene expression.
Conclusion: This study describes that GM-CSF negatively regulates IL-10-mediated responses.
Keywords: dendritic cells; granulocyte-macrophage colony-stimulating factor (GM-CSF); interleukin-10 (IL-10); macrophages; signal transduction.
Conflict of interest statement
Financial & competing interests disclosure This work was partly funded by Synthon BV, Nijmegen, The Netherlands. There was no additional external funding received for this study. Synthon BV supported this project financially but never interfered in the research approach. Furthermore, no patents or commercial products are under development based on this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Figures



References
-
- Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy – review of a new approach. Pharmacol. Rev. 2003;55(2):241–269. - PubMed
-
- Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113(2):383–389. - PubMed
-
- Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119(6):1461–1472. - PubMed
-
- Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289(5483):1352–1355. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources